These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Antiidiotypic antibodies carrying the "internal image" of peptide YIGSR inhibit spontaneous metastasis of Lewis lung carcinoma in mice.
    Author: Koliakos KK, Sapountzi Z, Papageorgiou A, Trachana V, Kotsinou S, Koliakos G.
    Journal: In Vivo; 2002; 16(6):511-8. PubMed ID: 12494895.
    Abstract:
    BACKGROUND: It has been reported that the laminin derivative synthetic peptide YIGSR can bind to a metastasis-associated laminin receptor and inhibit experimental metastasis. Several antiidiotypic antibody (anti-Id) vaccines have been used in clinical trials with promising results. We used an anti-Id vaccine based on peptide YIGSR for the inhibition of spontaneous metastasis in Lewis Lung carcinoma-bearing mice. MATERIALS AND METHODS: High titer anti-YIGSR serum from immunized rabbits was used to immunize sixteen Lewis Lung Carcinoma (LLC)-bearing mice. Another group of sixteen mice (controls) inoculated with LLC was immunized with control rabbit serum. After 24 days of tumor growth, the volume of the tumor was estimated, a blood sample was collected and the lungs were examined macroscopically and microscopically for metastasis. The presence of anti-Id antibodies was detected by Western blotting, ELISA and inhibition of cell attachment assays. RESULTS: Tumor growth was limited and metastasis was inhibited in the mice that received the anti-Id YIGSR vaccine as compared to controls. Both groups of mice developed anti-rabbit antibodies as indicated by Western blotting. However only the serum of mice immunized with high titer anti-YIGSR rabbit serum (anti-Id YIGSR vaccine) could inhibit the binding of the anti-YIGSR rabbit serum to the peptide YIGSR in ELISA assays. In addition the serum of mice that received the anti-Id YIGSR vaccine but not the controls inhibited cell attachment to the peptide on solid face assays. CONCLUSION: An anti-Id antimetastatic vaccine may be developed based on YIGSR.
    [Abstract] [Full Text] [Related] [New Search]